Who is sponsoring NCT07515261?

NCT07515261 is sponsored by Changping Laboratory.

What drugs are being tested in NCT07515261?

Interventions in NCT07515261: active iTBS.

What condition does NCT07515261 study?

NCT07515261 studies Autism Spectrum Disorder With Language Delay.

Is NCT07515261 still recruiting?

NCT07515261 is currently completed. Last updated 7 April 2026.

Last reviewed 2026-04-07 · How we verify

NCT07515261

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

pBFS Guided Neuromodulation Over DMPFC for ASD Treatment: Pilot Study

Completed NA Last updated 7 April 2026

What this trial tests

NA trial testing active iTBS in Autism Spectrum Disorder With Language Delay in 22 participants. Completed in 1 May 2024.

Timeline

10 March 2023

Primary endpoint
27 February 2024

1 May 2024

Quick facts

Lead sponsor	Changping Laboratory
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	22
Start date	10 March 2023
Primary completion	27 February 2024
Estimated completion	1 May 2024
Sites	1 location across China

Drugs / interventions tested

active iTBS

Conditions studied

Autism Spectrum Disorder With Language Delay — all drugs for Autism Spectrum Disorder With Language Delay →

Sponsor

Changping Laboratory

Who can join

Adults 6 to 30, any sex, with Autism Spectrum Disorder With Language Delay. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study will evaluate the feasibility and preliminary efficacy of pBFS-guided TMS treatment at DMPFC in autism spectrum disorder comorbid with language delay.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of active iTBS

Trials testing the same drug.

NCT06950437 — pBFS Guided aiTBS Over Language Network for ASD Child · NA · recruiting
NCT06031948 — pBFS-guided Noninvasive Neuromodulation for Pre-school Children With ASD · NA · unknown
NCT05735262 — pBFS Guided Precision Neuromodulation Treatment for ASD · NA · unknown
NCT05607654 — The Mechanisms of Underlying Accelerated Repetitive Transcranial Magnetic Stimulation for Treatment-resistant Depression · NA · recruiting
NCT05890846 — Precision TMS Treatment Guided by Personalized Brain Functional Sectors (pBFS) for ASD · NA · recruiting

Other Changping Laboratory trials

Trials by the same sponsor.

NCT06350396 — pBFS-guided rTMS Over DMPFC for Treatment-Resistant Depression · NA · recruiting
NCT06255535 — pBFS Guided rTMS Over Cognitive Control Network for ASD · NA · recruiting
NCT06255561 — pBFS Guided rTMS Over Different Targets for Treatment-Resistant Depression · NA · unknown
NCT06166082 — Stanford Neuromodulation Therapy (SNT) for the Treatment-Resistant Depression · NA · unknown
NCT06112652 — Neuromodulation of Different Doses to Treat TRD Guided by pBFS Technique · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07515261 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Changping Laboratory
Last refreshed: 7 April 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07515261.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing